Argo Biopharma's siRNA Therapy Shows Strong Phase II Results for HAE
Event summary
- Argo Biopharma presented updated Phase II data for BW-20805 at the Bradykinin Symposium 2026, showing significant reductions in HAE attack rates.
- BW-20805 demonstrated mean attack rate reductions of 83% to 96% across three dosing regimens.
- The therapy achieved sustained plasma prekallikrein (PKK) suppression and a well-tolerated safety profile.
- Study included 25 participants with HAE type 1 or 2, evaluating long-interval dosing regimens.
The big picture
Argo Biopharma's positive Phase II results for BW-20805 highlight the potential of siRNA therapeutics in treating rare genetic conditions like HAE. The data supports the need for long-acting, preventive therapies in a market currently dominated by frequent-dosing treatments. The company's focus on RNAi therapeutics aligns with broader industry trends toward targeted gene-silencing approaches for chronic and rare diseases.
What we're watching
- Clinical Progression
- Whether Argo Biopharma can advance BW-20805 to Phase III trials based on these positive results.
- Market Differentiation
- How the durability and less frequent dosing of BW-20805 will position it against existing HAE treatments.
- Regulatory Pathway
- The pace at which regulatory approvals could be achieved for this novel siRNA therapy.
Related topics